Dr Michelle Lockley
Dr Michelle Lockley is a consultant medical oncologist specialising in the systemic treatment of gynaecological cancers, with particular expertise in ovarian cancer and clinical trials. She has a special interest in the treatment of rare ovarian cancer sub-types.
Bio
Dr Lockley is a Medical Oncology Consultant at University College Hospital, London. She specialises in the management of gynaecological cancers, particularly ovarian cancer. She is committed to providing the best systemic treatments for women with gynaecological cancers and has lead numerous clinical trials. Her clinical interests extend to rare gynaecological malignancies, particularly germ cell tumours. she has published extensively in this area and is a member of 'MaGIC', the Malignant Germ cell International Consortium, where she Co-Lead the Translational Committee.
She held an Advanced Clinician Scientist Fellowship from Cancer Research UK and runs a laboratory research programme at Barts Cancer Institute, Queen Mary University of London. Her team aims to discover new treatments for difficult to treat cancers. She is particularly interested in developing new strategies to prolong the activity of anticancer treatments and prevent the development of resistance to therapy.
More information
- Consultant in Medical Oncology
University College London Hospital - Queen Mary University of London
Reader in Medical Oncology
- MSc Module Lead: Clinical Cancer Treatment
Queen Mary University of London
- Ovarian cancer
- Chemotherapy
- Clinical trials
- Year qualified 1997
- University College London
Authors: Silva VL, Saxena J, Nicolini F, Hoare JI, Metcalf S, Martin SA and Lockley M
Year: 2021
Authors: Newton C, Murali K, Ahmad A, Hockings H, Graham R, Liberale V, Sarker SJ, Ledermann J, Berney DM, Shamash J, Banerjee S, Stoneham S, Lockley M.
Year: 2019
Copy number signatures and mutational processes in ovarian carcinoma.
Authors: Macintyre G, Goranova TE, De Silva D, Ennis D, Piskorz AM, Eldridge M, Sie D, Lewsley LA, Hanif A, Wilson C, Dowson S, Glasspool RM, Lockley M, Brockbank E, Montes A, Walther A, Sundar S, Edmondson R, Hall GD, Clamp A, Gourley C, Hall M, Fotopoulou C, Gab
Year: 2018
Multiple competitive grant awards as Principal Investigator including:
- Barts Charity Large Project Grant (2021 - 2024)
“ACTOv Trial: Adaptive ChemoTherapy for Ovarian cancer”
£496,115.16 - Barts Cancer Institute Incentivisation Fund (2018 – 2021)
“Repurposing Fluticasone to improve platinum efficacy in (high-grade serous) ovarian cancer”
£190,000 - Industrial R&D grant: Academic collaboration with OCTIMET Oncology NV (2018 - 2020)
“Unravelling the mode of action of proprietary MET kinase inhibitors”
£443,531 - Advanced CRUK Clinician Scientist Fellowship (2016 - 2021)
“New treatments for chemotherapy-resistant high grade serous ovarian cancer”
£1,177,994 - Barts and The London Charity Strategic Research Grant (2014 - 2019)
“Discovering new therapies for chemotherapy resistant high grade serous ovarian cancer”
£197,545 - CRUK Clinician Scientist Fellowship (2011 - 2016)
“Inflammatory Cytokines and Oncolytic Adenoviruses in Ovarian Cancer”
£852,327
Member of research committees:
- Research Advisory Committee
The Eve Appeal - CRUK Experimental Medicine Expert Review Panel
Cancer Research UK - Scientific Evaluation Committee for Translational Cancer Research
French National Cancer Institute (INCa) - Chief Investigator for Barts/UCH Gynae Tissue Bank; set up and continues to lead this repository of tissues and clinical data kindly donated by patients for use in cancer research
Member of:
- MaGIC (Malignant Germ cell International Consortium)
- National Cancer Research Institute (NCRI) Early Onset Working Party
- NCRI Gynaecological Cancers Clinical Study Group